Back to Journals » Biologics: Targets and Therapy » Volume 6

Clinical utility of targeted treatments in the management of epithelial ovarian cancer

Authors Twu C, Han E

Received 20 December 2011

Accepted for publication 4 April 2012

Published 26 July 2012 Volume 2012:6 Pages 233—244

DOI https://doi.org/10.2147/BTT.S29356

Review by Single-blind

Peer reviewer comments 3


Cheryl Twu,1 Ernest S Han2

1Department of Women’s Health, Arrowhead Regional Medical Center, Colton, CA, USA; 2Division of Gynecologic Oncology, City of Hope, Duarte, CA, USA

Abstract: Epithelial ovarian cancer is typically found in its advanced stages, where a combination of surgical debulking and platinum/taxane-based chemotherapy is recommended. Although over 70%–80% of patients achieve remission, a significant proportion develop recurrence of their disease. Additional cytotoxic chemotherapy, as well as surgery, is typically used to manage disease recurrence. Therapies that target specific pathways in cancer cells are rapidly developing in the laboratory and are increasingly being studied in patients with ovarian cancer. We review the current status of novel therapies in the management of epithelial ovarian cancer.

Keywords: angiogenesis, polyadenosine ribose pathway inhibitors, epidermal growth factor receptor, folate inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]